REPL Replimune Group, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737953 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.6%
TTM EPS YoY19.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-115.8%
ROA-71.0%
ROIC (approx.)-209.7%
Asset turnover—
Leverage & solvency
Liabilities / assets45.2%
Debt / equity0.49x
Current ratio7.11x
Interest coverage-30.18x
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $34.37M | $49.28M | $52.32M | $53.14M | $57.88M | $57.84M | $53.98M | $48.00M |
| SG&A expense | $21.92M | $18.97M | $21.01M | $18.73M | $26.41M | $32.58M | $25.35M | $18.02M |
| Operating income | -$56.28M | -$68.25M | -$73.34M | -$71.87M | -$84.29M | -$90.42M | -$79.33M | -$66.02M |
| Interest expense | $2.52M | $2.58M | $2.37M | $1.47M | $1.49M | $1.48M | $1.46M | $1.45M |
| Pretax income | — | — | -$73.46M | -$71.24M | — | — | -$74.24M | -$65.77M |
| Income tax | — | — | -$240,000 | -$311,000 | $0 | $0 | -$107,000 | $575,000 |
| Net income | -$57.12M | -$69.77M | -$73.22M | -$70.93M | -$83.10M | -$86.69M | -$74.13M | -$66.34M |
| EBITDA | -$55.48M | -$67.31M | -$72.57M | -$71.07M | -$83.49M | -$89.55M | -$78.48M | -$65.02M |
| EPS (basic) | -0.54 | -0.72 | — | -0.77 | -0.90 | -0.95 | — | -0.79 |
| EPS (diluted) | -0.54 | -0.72 | — | -0.77 | -0.90 | -0.95 | — | -0.79 |
| Weighted avg. shares (diluted) | 105.18M | 96.86M | — | 92.19M | 91.92M | 91.52M | — | 83.50M |
| Balance sheet | ||||||||
| Cash & equivalents | $307.83M | $185.36M | $209.02M | $122.95M | $104.00M | $99.08M | $112.82M | $173.94M |
| Short-term investments | $0 | $9.97M | $59.87M | $146.19M | $221.35M | $305.97M | $372.69M | $364.29M |
| Inventory | $9.87M | — | $0 | — | — | — | — | — |
| Current assets | $324.04M | $200.81M | $279.12M | $280.35M | $333.75M | $413.37M | $495.88M | $547.58M |
| PP&E, net | $10.70M | $11.86M | $12.97M | $13.85M | $14.71M | $14.68M | $13.74M | $13.62M |
| Total assets | $373.94M | $252.45M | $332.39M | $333.59M | $389.45M | $469.51M | $551.33M | $603.63M |
| Current liabilities | $45.55M | $38.41M | $58.23M | $50.09M | $52.90M | $59.56M | $62.36M | $47.89M |
| Long-term debt | $99.77M | $84.11M | $83.31M | $47.63M | $47.21M | $46.79M | $46.38M | $45.96M |
| Total debt | $99.77M | $84.11M | $83.31M | $47.63M | $47.21M | $46.79M | $46.38M | $45.96M |
| Total liabilities | $169.16M | $146.80M | $166.23M | $123.05M | $126.11M | $132.79M | $135.49M | $121.25M |
| Shareholders' equity | $204.78M | $105.64M | $166.16M | $210.54M | $263.34M | $336.71M | $415.84M | $482.37M |
| Net debt | -$208.07M | -$101.25M | -$125.72M | -$75.32M | -$56.80M | -$52.29M | -$66.44M | -$127.98M |
| Shares outstanding | 94.81M | 83.98M | 82.72M | 79.63M | 78.40M | 77.81M | 77.09M | 77.01M |
| Cash flow statement | ||||||||
| Operating cash flow | -$47.70M | -$75.73M | -$56.16M | -$65.95M | -$81.21M | -$77.02M | -$53.73M | -$50.71M |
| Capital expenditure | $77,000 | $6,000 | $5,000 | $135,000 | $1.34M | $2.74M | $1.13M | $1.80M |
| Free cash flow | -$47.78M | -$75.73M | -$56.17M | -$66.09M | -$82.56M | -$79.76M | -$54.87M | -$52.51M |
| Investing cash flow | $9.76M | $49.99M | $86.51M | $75.12M | $84.17M | $65.05M | -$7.70M | -$46.32M |
| Financing cash flow | $160.55M | $800,000 | $55.68M | $10.45M | $324,000 | -$158,000 | -$132,000 | $155.93M |
| Depreciation & amortization | $800,000 | $937,000 | $769,000 | $800,000 | $800,000 | $873,000 | $848,000 | $1.00M |
| Stock-based compensation | $10.54M | $7.67M | $8.12M | $7.05M | $8.34M | $8.76M | $8.28M | $8.64M |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.